The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing, PR China.
Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Zhengzhou, PR China.
J Autoimmun. 2020 Aug;112:102465. doi: 10.1016/j.jaut.2020.102465. Epub 2020 Apr 21.
Combination of corticosteroids (CS) with cyclosporin A (CsA) is widely used in the treatment of autoimmune diseases, autoinflammatory diseases and transplantation rejection. However, some patients fail to respond or develop resistance to the combination regimen. In Vogt-Koyanagi-Harada (VKH) disease model, we performed RNA sequencing (RNA-seq) based transcriptomics, isobaric tags for relative and absolute quantification (iTRAQ) based proteomics and assays in vitro to screen and validate potential resistant molecules. We found that a total of 1697 differentially expressed genes (DEGs) and 21 differentially expressed proteins (DEPs) in CD4 T cells between CsA & CS-resistant and -sensitive VKH patients. Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4 T cells from male VKH patients to CsA & CS. Importantly, we showed that chlorambucil (CLB) could reverse the resistance by RPS4Y1 suppression. Taken together, we identify RPS4Y1 as an important CsA & CS resistance gene in VKH disease. Researchers should consider validating the resistant effect of RPS4Y1 in other autoimmune diseases or organ transplantation.
皮质类固醇(CS)与环孢素 A(CsA)联合治疗自身免疫性疾病、自身炎症性疾病和移植排斥反应已得到广泛应用。然而,部分患者对联合治疗方案无效或产生耐药性。在 Vogt-Koyanagi-Harada(VKH)疾病模型中,我们进行了基于 RNA 测序(RNA-seq)的转录组学、基于等重标记相对和绝对定量(iTRAQ)的蛋白质组学以及体外检测,以筛选和验证潜在的耐药分子。我们发现,CsA & CS 耐药和敏感 VKH 患者的 CD4 T 细胞之间共有 1697 个差异表达基因(DEGs)和 21 个差异表达蛋白(DEPs)。Ribosomal Protein S4, Y-Linked 1(RPS4Y1)被证实可调节男性 VKH 患者 CD4 T 细胞对 CsA & CS 的耐药性。重要的是,我们表明氯苯丁酸(CLB)可通过抑制 RPS4Y1 逆转耐药性。总之,我们确定 RPS4Y1 是 VKH 疾病中 CsA & CS 耐药的重要基因。研究人员应考虑在其他自身免疫性疾病或器官移植中验证 RPS4Y1 的耐药效果。